We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

23 hedge funds and large institutions have $48.9M invested in ProQR Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

28% more funds holding

Funds holding: 18 → 23 (+5)

1.64% more ownership

Funds ownership: 38.56% → 40.2% (+1.6%)

4% more capital invested

Capital invested by funds: $46.8M → $48.9M (+$2.06M)

Holders
23
Holders Change
+5
Holders Change %
+27.78%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$5.19M
2
SFM
Sphera Funds Management
Israel
+$1.04M
3
Morgan Stanley
Morgan Stanley
New York
+$205K
4
Wells Fargo
Wells Fargo
California
+$153K
5
NCCM
Nine Chapters Capital Management
New Jersey
+$142K

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$1.29M
2
Jennison Associates
Jennison Associates
New York
-$79.2K
3
O
OrbiMed
New York
-$52.4K
4
Creative Planning
Creative Planning
Kansas
-$10K
5
ClearBridge Investments
ClearBridge Investments
New York
-$6.34K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jennison Associates
1
Jennison Associates
New York
$11.9M -$79.2K -15,248 -0.6%
O
2
OrbiMed
New York
$11.1M -$52.4K -10,100 -0.4%
RG
3
Redmile Group
California
$7.77M +$34.8K +6,700 +0.4%
AG
4
Artal Group
Luxembourg
$7.28M +$5.19M +1,000,000 +200%
SFM
5
Sphera Funds Management
Israel
$2.57M +$1.04M +200,000 +61%
ClearBridge Investments
6
ClearBridge Investments
New York
$2.42M -$6.34K -1,222 -0.2%
Franklin Resources
7
Franklin Resources
California
$1.5M – – –
Fidelity Investments
8
Fidelity Investments
Massachusetts
$1.15M – – –
AGA
9
Altrinsic Global Advisors
Connecticut
$928K – – –
Janus Henderson Group
10
Janus Henderson Group
United Kingdom
$690K -$1.29M -247,659 -64%
Morgan Stanley
11
Morgan Stanley
New York
$491K +$205K +39,428 +64%
Principal Financial Group
12
Principal Financial Group
Iowa
$395K +$26K +5,000 +7%
Wells Fargo
13
Wells Fargo
California
$210K +$153K +29,400 +213%
NCCM
14
Nine Chapters Capital Management
New Jersey
$133K +$142K +27,400 New
PCM
15
Prelude Capital Management
New York
$71K +$74.8K +14,400 +4,800%
VF
16
Virtu Financial
New York
$64K +$68.3K +13,150 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$59K -$4.08K -786 -6%
Deutsche Bank
18
Deutsche Bank
Germany
$46K +$49.3K +9,500 New
TRCT
19
Tower Research Capital (TRC)
New York
$14K +$15.3K +2,939 New
UBS Group
20
UBS Group
Switzerland
$12K +$3.35K +646 +37%
TDC
21
Thompson Davis & Co
Virginia
$10K +$10.4K +2,000 New
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$4K +$1.04K +200 +38%
Creative Planning
23
Creative Planning
Kansas
– -$10K -1,900 Closed
Acadian Asset Management
24
Acadian Asset Management
Massachusetts
– +$519 +100 New

PRQR Hedge Fund Activity: Q3 2017 in Review

23 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2017, worth a combined $48.9M — up 4.4% from $46.8M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new PRQR positions and 1 closed out — a net gain of 5 holders — while 9 added to existing stakes and 5 trimmed.

The largest buyer was Artal Group, adding an estimated $5.19M. The largest seller was Janus Henderson Group, cutting an estimated $1.29M.

  • 23 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2017, up from 18 in Q2 2017.
  • Funds reported $48.9M of ProQR Therapeutics stock for Q3 2017, up 4.4% quarter-over-quarter.
  • 6 funds opened new ProQR Therapeutics positions in Q3 2017 and 1 closed out, a net change of +5 holders.
  • The largest ProQR Therapeutics buyer in Q3 2017 was Artal Group, an estimated $5.19M added.
  • The largest ProQR Therapeutics seller in Q3 2017 was Janus Henderson Group, an estimated $1.29M sold.

Based on aggregated 13F filings for Q3 2017.